Covid-19: Adolescents likely to get Zydus Cadila DNA vaccine after 4 weeks

Published On 2021-08-24 08:06 GMT | Update On 2021-08-24 08:06 GMT

New Delhi: The Drugs Controller General of India (DCGI) on Friday approved Zydus Cadila's DNA vaccine for emergency use in adults and children aged 12 years and above.

It is considered a timely move amid warnings of an upcoming third wave in the country. Recently, a committee of experts under the National Institute of Disaster Management (NIDM) warned of the third COVID-19 wave that could peak around October and sought better preparedness for children.

Dr Renu Swarup, Secretary, Department of Biotechnology, Government of India, while speaking exclusively to on vaccines for children in India and use of Zydus Cadila's ZyCoV-D for above 12 years adolescents, said, "So far the vaccines which were in the market were those which were for above 18 years. This is the DNA vaccine that has just received emergency use authorization is for 12 to 18 years and above. For the younger children, maybe 5 to 12 years, and even below there are different stages of the research which is still going on, and mostly all the vaccine manufacturers on different platforms are doing their trials."

Dr Swarup added, "We know that Bharat biotech has already got permission for the trial of a vaccine which is again for younger children five years and above. Similarly, the biological E is still in their phase three trials. Currently, it's now doing its phase 2, phase 3 for which it got approval for the trials on children."

"So, most of the vaccine developers are working but that's going to take a little while it's very difficult to say when. But they are already working on it, but this is for 12 and above. It is a good development, and we hope that this is going to make a major difference," she further said.

When asking about the administering of ZyCoV-D to Children she said, "DNA vaccine which has just received emergency use authorization. we've just been informed that this was going to take about four weeks before they can bring out the doses for the immunisation programme, which children will get immunised. It will be taken by the entire NTAGI Working Group on COVID because they will have to decide, considering how much volume is going to be available. Knowing this, that this is a new technology, a new platform, it does take time for the scale-up of this vaccine."

"The schedule of the dosing for which category of children will be guided by the NTAGI the working group based on a number of parameters that they will consider, and that's how the decision will be taken," she added.

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Covid-19: Adolescents likely to get Zydus Cadila DNA vaccine after 4 weeks

Similar News

Racket manufacturing fake medicines busted, factory owner held

Sigachi Pharma Plant explosion toll rises to 46, 8 still missing

Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility

JnJ gets USFDA priority review for TAR 200 NDA in high-risk non-muscle invasive bladder cancer

Zydus Asked to Revise Phase III Trial Protocol for Cough Syrup FDC After CDSCO Panel Review

Illegal sale of abortion kits: Show cause notice issued to 149 medical shops in Telangana

Granules India CEO Dr Kandiraju Venkata Sitaram Rao to step down

Torrent Pharma seeks CCI clearance to acquire majority stake in JB Pharma in Rs 19500 crore deal